Watchlist Price Alert

Clearside Biomedical Inc. (CLSD)

NASDAQ: CLSD · Real-Time Price · USD

0.79

0.02 (1.94%)

At close: Jun 06, 2025, 3:36 PM

1.94% (1D)

Bid	0.78
Market Cap	61.62M
Revenue (ttm)	1.43M
Net Income (ttm)	-30.81M
EPS (ttm)	-0.41
PE Ratio (ttm)	-1.93
Forward PE	-1.25
Analyst	Buy

Ask	0.8
Volume	196,589
Avg. Volume (20D)	158,171
Open	0.78
Previous Close	0.78
Day's Range	0.76 - 0.82
52-Week Range	0.70 - 1.65
Beta	2.06

About CLSD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CLSD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CLSD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+14.82%

Clearside Biomedical shares are trading higher aft... Unlock content with Pro Subscription

11 months ago

+15.74%

Clearside Biomedical shares are trading higher after Oppenheimer initiated coverage with an Outperform rating and a price target of $5.

News

1 week ago · zacks.com

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · zacks.com

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.

1 month ago · zacks.com

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · seekingalpha.com

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Ch...

2 months ago · zacks.com

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.08 per share a year ago.